Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss

By Cory Renauer - Updated Apr 22, 2019 at 11:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Results from a few clinical trials reading out in 2019 could make it a year to remember.

Gilead Sciences ( GILD -0.16% ) stock has been sliding for years, but the biotech has the right ingredients to stage a comeback and provide market-thumping gains down the road. Gilead's new HIV pill is a hit, and it has a couple of drugs in late-stage trials that could do just as well.

Of course, this biotech stock isn't going anywhere if ongoing clinical trials don't produce the right results. Here's what you need to know about three clinical trial readouts on the horizon that could smooth out a path to growth for Gilead -- or put up barriers.

Check out the latest Gilead Sciences earnings call transcript.

Three pill bottles on a conveyor belt with cash money stuffed inside.

Image source: Getty Images.

1. Glaxo's new two-drug HIV combo

Last February, Gilead introduced Biktarvy, a single-pill regimen for HIV that's already the company's lead growth driver. Biktarvy's approved to treat patients switching from another antiviral, and those new to treatment. A large patient population on the lifelong medication is expected to drive annual sales to $5 billion by 2022. 

Gilead Sciences investors want to keep an eye on a two-drug combination from GlaxoSmithKline ( GSK -0.53% ) that's in a pair of head-to-head studies with an older three-drug regimen still used to treat newly diagnosed patients. Glaxo's next challenger to Gilead's lead in the HIV space combines dolutegravir with lamivudine (which suppressed the virus after 48 weeks), as well as dolutegravir, tenofovir disoproxil fumarate, and emtricitabine for patients new to treatment.

In the third quarter, GlaxoSmithKline will present 96-week results for its two-drug candidate. Gilead investors will want to keep an eye open for the results to see how the potential competitor stacks up to Biktarvy.

A healthcare professional holding out a lit light bulb.

Image source: Getty Images.

2. Selonsertib for NASH

Nonalcoholic steatohepatitis (NASH) is a progressive condition that describes an immune system persistently attacking fatty liver tissue. Around one-third of American adults have livers with dangerous fat levels, or nonalcoholic fatty liver disease (NAFLD), but few realize it unless they become one of an estimated 20 million in the U.S. with the persistent inflammation that defines NASH.

NASH progresses so slowly that the Food and Drug Administration is willing to grant accelerated approval of treatments for advanced-stage patients with liver tissue already scarred and stiffened by inflammation. Specifically, it wants to see drugs that stop the inflammation without fibrosis worsening, or reduce fibrosis without inflammation worsening.

In the first half of the year, Gilead will present top-line data from pivotal studies with selonsertib as a treatment for patients with bridging fibrosis, and another for patients with compensated cirrhosis caused by NASH. If Gilead's NASH candidate performs in line with earlier observations, it could carve out a niche among severely affected NASH patients capable of driving annual sales past $1 billion in a few short years. During a mid-stage study, selonsertib helped 43% of patients achieve a fibrosis score improvement compared with just 2 out of 10 patients given a placebo.

Selonsertib's mid-stage data was positive but difficult to interpret because of the small groups. That means anything can happen when Gilead reads out the results. 

A doctor accepting money.

Image source: Getty Images.

3. Filgotinib for rheumatoid arthritis

The world's top-selling drug, Humira, hauled in around $20 billion last year as an anti-inflammatory injection for people with rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease. Gilead's filgotinib is an easy-to-swallow tablet in late-stage pivotal trials for the treatment of RA, which puts it far behind a couple other similar candidates ready to break into this space.

Last year, Eli Lilly ( LLY -0.93% ) launched a new, easy-to-swallow tablet for rheumatoid arthritis called Olumiant, but the FDA restricted the dosage to a level that probably won't be very effective. The agency was troubled by a very small number of patients who experienced life-threatening blood clots during studies with Olumiant. AbbVie ( ABBV 1.69% ) is waiting for the FDA to review an application submitted late last year for upadacitinib, another oral RA therapy with a safety record besmirched by a small number of lethal clots during phase 3 trials. 

During the Finch-2 study with filgotinib, RA patients who didn't respond well to Humira, or other injectables, achieved improvements after 12 weeks that suggest filgotinib can stand up to Olumiant and upadacitinib. Moreover, it hasn't been associated with dangerous blood clots yet.

Investigators will present data from two more Finch studies before the end of the first quarter. If Gilead's RA hopeful can maintain a squeaky-clean safety profile, there's a good chance it will also become the best-selling new rheumatoid arthritis treatment, with potential expansions to inflammatory bowel disease down the road.

Person pulling money out of a wallet.

Image source: Getty Images.

A bargain now?

Gilead's diminished hepatitis C franchise contributes just 16% of total revenue now. That means continued commercial success with Biktarvy might be enough to return the company's sagging top line to growth on its own.

Shares of the biotech have fallen to just 10.2 times forward earnings expectations. That looks like a bargain compared with the average S&P 500 stock, which currently trades at around 15.7 times estimates.

Gilead also offers a nice 3.3% dividend yield at recent prices, and HIV sales generate plenty of cash to make the payments and keep raising them each year. It's hard to predict what's going to happen with filgotinib and selonsertib, but those quarterly payouts are yours to keep.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$69.56 (-0.16%) $0.11
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$41.25 (-0.53%) $0.22
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$245.58 (-0.93%) $-2.30
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$118.85 (1.69%) $1.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.